About the Rutgeerts Score for Postoperative Crohn's Disease Recurrence
Endoscopy at six to twelve months after ileocolonic resection sees recurrence long before the patient feels it — that gap is the entire reason this score exists. The Rutgeerts score grades the neoterminal ileum from i0 (no lesions) through i1 (five or fewer aphthous lesions), i2 (more than five with normal intervening mucosa, skip areas of larger lesions, or lesions confined to the anastomosis), i3 (diffuse aphthous ileitis with diffusely inflamed mucosa) to i4 (large ulcers, nodules or stenosis). In the original cohort 73% had endoscopic recurrence within a year while only 20% had symptoms. i2 and above is where escalation of therapy is generally recommended.
Interpreting the result
i0 and i1 are treated together in practice: both carry a course close to remission, and neither mandates escalation on endoscopic grounds. From i2 upward the grades predict clinical and surgical recurrence, and i2 is where guidelines expect therapy to be stepped up. The complication is i2 itself, which as originally written bundles two different situations — scattered lesions in the neoterminal ileum, and lesions confined to the anastomosis. The modified score separates them as i2b and i2a because anastomotic lesions appear to progress less often, and there is a reasonable argument that some i2a findings represent ischaemic or mechanical change at the suture line rather than recurrent Crohn's disease at all. That argument is not settled, and at least one substantial analysis found the modification did not change decisions about recurrence or the need for intervention. i3 and i4 are unambiguous: diffuse inflammation or large ulcers with nodules or stenosis carry the highest risk of progression, and i4 in particular should prompt an assessment of whether a stricture is contributing to symptoms mechanically.
| Score | Band | What it means | Action |
|---|---|---|---|
| i0 | No endoscopic recurrence | No lesions in the neoterminal ileum. Lowest risk of subsequent clinical recurrence | Continue current management; no escalation on endoscopic grounds. Reassess per local protocol |
| i1 | Mild endoscopic recurrence | Five or fewer aphthous lesions. Counts as endoscopic recurrence but behaved similarly to i0 in the original cohort | Escalation not mandated. Address modifiable risk — smoking above all — and plan repeat assessment |
| i2a | Moderate — confined to the anastomosis | Lesions limited to the ileocolonic anastomosis, including anastomotic stenosis. Appears to carry lower risk than i2b | Genuinely contested. Exclude a mechanical stricture as the cause of symptoms; discuss whether escalation is warranted |
| i2b | Moderate — neoterminal ileum | More than five aphthous ulcers or larger lesions in the neoterminal ileum with normal mucosa between | The conventional escalation threshold. Step up therapy and reassess endoscopically in 6–12 months |
| i3 | Severe endoscopic recurrence | Diffuse aphthous ileitis with diffusely inflamed mucosa between the lesions. Predicts clinical and surgical recurrence | Escalate therapy; confirm with biopsies and reassess after 6–12 months of the new regimen |
| i4 | Severe with ulceration or stenosis | Large ulcers with diffuse mucosal inflammation, or nodules or stenosis in the neoterminal ileum. Highest risk of progression | Escalate; assess whether a stricture is contributing mechanically, and involve surgery in the discussion |
What the Rutgeerts Score needs (2 inputs)
- Endoscopic appearance of the neoterminal ileum
- A single ordinal grade, i0 to i4, taken as the highest whose features are present. Assessed at ileocolonoscopy after ileocolonic resection, looking specifically at the neoterminal ileum and the anastomosis.
- Location of i2 lesions (modified score)
- Only asked when the grade is i2. i2a means lesions confined to the ileocolonic anastomosis including anastomotic stenosis; i2b means more than five aphthous ulcers or larger lesions in the neoterminal ileum with normal mucosa between, with or without anastomotic lesions.
What it returns
- Rutgeerts grade (i0–i4)
- An ordinal grade, not a points total. Reported as i2a or i2b when the modified subdivision is used.
- Whether escalation is indicated
- i2 and above is the conventional threshold. The i2a subgroup is where that convention is genuinely contested.
How it is calculated
The grading was derived empirically from a prospective cohort rather than constructed by committee. Eighty-nine patients who had undergone ileal resection between 1979 and 1984 were followed with serial ileoscopy, and the appearance of the neoterminal ileum was graded and then related to what happened next. Two features of the resulting scale reflect that origin. It is ordinal and descriptive, with anchors a endoscopist can apply without measurement, because it had to be usable at the time of the procedure. And its categories are drawn where the observed course diverged — the separation between scattered aphthous lesions with normal mucosa between them and diffusely inflamed mucosa is the point at which the cohort's outcomes parted, not an arbitrary halfway mark. A companion observation in the same paper reframed what the lesions mean: of 22 additional patients with a macroscopically normal neoterminal ileum at surgery, 21 had developed ileitis by the six-month look, which established that these are new lesions rather than residual disease left behind by the surgeon.
Facts & figures
| Time after resection | Endoscopic recurrence | Symptomatic |
|---|---|---|
| 1 year | 73% | 20% |
| 3 years | 85% | 34% |
The gap between the two columns is the argument for scoping rather than waiting. At one year, roughly two-thirds of patients with recurrence had no symptoms to prompt investigation.
| Grade | Definition | Practical implication |
|---|---|---|
| i2 (original) | More than 5 aphthous lesions with normal intervening mucosa, OR skip areas of larger lesions, OR lesions confined to the anastomosis | Bundles anastomotic and neoterminal ileal disease into one category |
| i2a (modified) | Lesions confined to the ileocolonic anastomosis, including anastomotic stenosis | May reflect ischaemic or mechanical change rather than recurrent Crohn's; lower observed risk |
| i2b (modified) | More than 5 aphthous ulcers or larger lesions in the neoterminal ileum, normal mucosa between, with or without anastomotic lesions | Behaves like the recurrence the score was built to detect; the clearer escalation trigger |
Trial literature reports the original five-grade score, so record that alongside any modified grade. An analysis of the modification found it did not change determinations of recurrence or the need for intervention, so the split remains informative rather than decisive.
Evidence
Derivation — prospective cohort, Leuven
1990 · n = 89Patients treated by ileal resection for Crohn's disease between 1979 and 1984, followed prospectively with serial ileoscopy to study the natural course of early postoperative lesions.
Endoscopic recurrence appeared in 73% within one year with only 20% symptomatic, and reached 85% by three years with 34% symptomatic. The severity of the early postoperative endoscopic findings predicted subsequent disease course better than other variables, alongside preoperative disease activity, the indication for surgery and the number of previous resections.
New lesions, not residual disease — companion cohort
1990 · n = 22A further 22 patients in the same publication, all with a macroscopically normal neoterminal ileum at the time of surgery.
Twenty-one had developed ileitis by the six-month follow-up ileoscopy and 20 had microscopic lesions on biopsy, establishing that postoperative lesions are newly developed rather than disease left behind at resection.
Treat-to-target using the score — POCER trial
2015Randomised trial of active care with colonoscopy at six months and treatment step-up for recurrence, versus standard care, after intestinal resection for Crohn's disease.
Endoscopic monitoring with escalation for recurrence reduced endoscopic recurrence at 18 months compared with standard drug therapy alone, supporting the strategy of scoping and acting rather than treating empirically.
Guideline adoption — AGA 2017 and ECCO 2016
2017The AGA Institute guideline on management of Crohn's disease after surgical resection and the 3rd European evidence-based consensus on Crohn's disease.
Both recommend endoscopic assessment 6–12 months after resection and use the Rutgeerts grading to decide whether to escalate therapy, rather than treating on symptoms alone.
How it compares
Rutgeerts Score vs Harvey-Bradshaw Index
They disagree by design — Harvey-Bradshaw measures how the patient feels and Rutgeerts measures what the anastomosis looks like, and in the first year after surgery the second is far ahead of the first.
The original cohort quantified the divergence: 73% endoscopic recurrence at one year against 20% symptomatic. A patient in clinical remission by Harvey-Bradshaw can be i3 or i4, and that combination is common rather than exceptional. The practical consequence is that a normal clinical index is not a reason to skip the postoperative colonoscopy, which is precisely the error the score exists to prevent. Use Harvey-Bradshaw to track symptoms and response over time; use Rutgeerts to decide whether prophylaxis needs stepping up.
Rutgeerts Score vs Modified Rutgeerts score (i2a/i2b)
The modification adds information about where the lesions are but has not displaced the original — trial literature still reports i0–i4, so record both.
Splitting i2 addresses a genuine ambiguity: the original category covers both scattered neoterminal ileal lesions and disease confined to the anastomosis, and there is reasonable evidence that the latter progresses less often and may sometimes reflect ischaemic or mechanical change at the suture line rather than recurrent Crohn's. Against that, an analysis of the modification found it did not alter determinations of recurrence or the need for endoscopic or surgical intervention. The sensible position is that i2a versus i2b is worth recording and worth weighing in a borderline decision, but it is not yet a licence to withhold escalation.
Rutgeerts Score vs SES-CD
Different anatomical questions — SES-CD scores Crohn's activity across five colonic segments, while Rutgeerts scores one specific site after one specific operation.
The Simple Endoscopic Score for Crohn's Disease grades ulcer size, ulcerated surface, affected surface and stenosis across five segments, and is the instrument for endoscopic activity in Crohn's generally, including as a trial endpoint for mucosal healing. It is not designed for the postoperative neoterminal ileum and does not carry the outcome data that makes Rutgeerts predictive in that setting. Conversely, Rutgeerts says nothing about disease elsewhere in the bowel. A patient with recurrent disease at the anastomosis and active colonic disease needs both recorded.
Pearls & pitfalls
- The score grades the neoterminal ileum after ileocolonic resection. It is not validated after colonic resection or strictureplasty, and applying it there gives a number that means nothing.
- i1 is five or fewer aphthous lesions and i2 begins above five. Counting matters more here than anywhere else in the scale, because five and six lesions sit either side of the escalation threshold.
- Take the highest grade whose features are present. A patient with scattered aphthae and one large ulcer with surrounding diffuse inflammation is i3 or i4, not i2.
- Lesions confined to the anastomosis are i2 under the original score — which is exactly why the modified i2a exists. Record which version you used.
- Do not assume i2a means no action. The evidence that it progresses less is real but not decisive, and one analysis found the modification changed neither recurrence determination nor the need for intervention.
- An anastomotic stricture can cause obstructive symptoms without active inflammation. At i2a and i4 especially, work out whether symptoms are mechanical before escalating immunosuppression.
- Endoscopic and clinical activity diverge routinely. A patient with a Harvey-Bradshaw Index in the remission range can be i4, and treating on symptoms alone is the practice this score was written to displace.
- Smoking is the strongest modifiable predictor of postoperative recurrence. Recording an i2 and not addressing smoking misses the intervention with the largest effect available.
- Six to twelve months is the conventional window. Scoping much earlier risks grading changes that have not yet declared; much later gives up the preventive opportunity.
Critical actions
- Perform ileocolonoscopy 6–12 months after ileocolonic resection regardless of symptoms — this is a guideline recommendation, not a discretionary check.
- Record the grade explicitly in the endoscopy report, and say whether you used the original or the modified score.
- Photograph or describe the anastomosis separately from the neoterminal ileum, so a later reader can tell i2a from i2b.
- Escalate therapy at i2b and above; the evidence supports treating endoscopic recurrence rather than waiting for symptoms.
- Address smoking at every grade, including i0 — it is the single largest modifiable risk factor for recurrence.
- Where a stricture is present, establish whether it is inflammatory or fibrotic before assuming immunosuppression will help.
- Reassess endoscopically 6–12 months after any escalation, to confirm the change achieved something.
- Do not use the grade as a measure of overall Crohn's activity — pair it with a clinical index and objective inflammatory markers.
Why this score exists
The paper set out to answer a natural-history question rather than to build a score: what actually happens to the neoterminal ileum after resection, and can the early appearance predict the later course. Two of its findings did more to change practice than the grading itself. The first was the size of the gap between endoscopic and symptomatic recurrence, which made the case that postoperative management should be guided by looking rather than waiting. The second was the companion observation in 22 patients with a normal ileum at surgery, 21 of whom had ileitis six months later — that ruled out the then-plausible explanation that recurrence reflected disease the surgeon had failed to remove, and reframed the postoperative period as a window in which new disease develops and might therefore be prevented. The grading exists because the authors needed a reproducible way to record severity in order to make those arguments, and it survived because it turned out to predict what happened next.
About the creator
First author, 1990 derivation cohort
Led the prospective ileoscopy cohort that defined the grading and established the gap between endoscopic and symptomatic recurrence.
Co-author; histopathology
Provided the histological assessment showing that postoperative lesions were newly developed rather than residual.
Senior author
Senior author of the Leuven cohort that produced the score.
Limitations
- Derived from a single-centre cohort of 89 patients operated on between 1979 and 1984, decades before biologics changed the postoperative landscape.
- Inter-observer agreement is imperfect, particularly around the i1/i2 boundary where the distinction rests on counting aphthous lesions.
- The original i2 category conflates anastomotic and neoterminal ileal disease, which is the ambiguity the modified score attempts to resolve and has not fully settled.
- Anastomotic lesions may reflect ischaemia, suture material or mechanical factors rather than recurrent Crohn's disease, and the score has no way to distinguish these.
- Ordinal, not interval — the clinical distance from i0 to i1 is not the same as from i2 to i3, so grades should not be averaged or trended arithmetically.
- Validated for ileocolonic resection only; there is no equivalent validated grading after colonic resection or strictureplasty.
- Says nothing about disease elsewhere in the bowel, or about extraintestinal manifestations.
- The 6–12 month window is convention supported by outcome data rather than a precisely optimised interval, and practice varies.
If you are the patient
After an operation to remove the diseased end of the small bowel in Crohn's disease, the disease often starts to come back at the join — usually long before you would notice anything. That is why your team will arrange a camera test, a colonoscopy, somewhere between six and twelve months after surgery even if you feel completely well. The Rutgeerts score is how they write down what they see, from i0 meaning no sign of disease, through i1 and i2 for small scattered ulcers, up to i3 and i4 for more widespread inflammation, larger ulcers or narrowing. The reason for looking early is straightforward: in the original study, about three-quarters of people had visible recurrence within a year but only one in five had any symptoms. Catching it at that stage means treatment can be strengthened before damage builds up. If the score is i2 or higher, your team will usually suggest stepping up medication and repeating the camera test in another six to twelve months to check it has worked. One thing genuinely within your control matters more than any medication here: stopping smoking is the single biggest thing that reduces the chance of Crohn's coming back after surgery, so if you smoke, ask for help with quitting.
Frequently asked questions
What is the Rutgeerts score?#
An endoscopic grading of postoperative Crohn's disease recurrence in the neoterminal ileum, scored at ileocolonoscopy six to twelve months after ileocolonic resection. It runs i0 (no lesions), i1 (five or fewer aphthous lesions), i2 (more than five with normal intervening mucosa, skip areas of larger lesions, or lesions confined to the anastomosis), i3 (diffuse aphthous ileitis with diffusely inflamed mucosa) and i4 (large ulcers, nodules or stenosis).
What Rutgeerts score means recurrence?#
i1 through i4 are all considered endoscopic recurrence, but the threshold that changes management is i2. Escalation of therapy is generally recommended from i2 upward, because i2 and above predict clinical and surgical recurrence, whereas i1 behaved much like i0 in the original cohort.
What is the difference between i2a and i2b?#
They are the modified score's split of the original i2 category. i2a is lesions confined to the ileocolonic anastomosis, including anastomotic stenosis. i2b is more than five aphthous ulcers or larger lesions in the neoterminal ileum with normal mucosa between, with or without anastomotic lesions. i2a appears to carry a lower risk of progression, possibly because some anastomotic lesions reflect ischaemic or mechanical change rather than recurrent Crohn's disease.
When should the colonoscopy be done after Crohn's surgery?#
Six to twelve months after ileocolonic resection, regardless of symptoms. Both the AGA guideline and the European consensus recommend this, and the POCER trial showed that scoping at six months and escalating therapy for recurrence reduced endoscopic recurrence at 18 months compared with drug therapy alone.
How often does Crohn's recur after surgery?#
In the original cohort, endoscopic recurrence appeared in 73% within one year and 85% by three years. Symptoms lagged far behind: 20% at one year and 34% at three years. That gap — most recurrence being silent at the point it becomes treatable — is the reason the postoperative colonoscopy is recommended rather than optional.
Are postoperative lesions leftover disease the surgeon missed?#
No, and the original paper settled this. Of 22 patients whose neoterminal ileum was macroscopically normal at the time of surgery, 21 had developed ileitis by the six-month ileoscopy and 20 had microscopic lesions on biopsy. The lesions develop after the operation, which is what makes the postoperative period a window for prevention rather than a matter of incomplete resection.
Can you have a normal Rutgeerts score but still feel unwell?#
Yes, and the reverse is far more common. Endoscopic and symptomatic recurrence diverge substantially — a patient can be i4 with a Harvey-Bradshaw Index in the remission range, or symptomatic at i0 from bile-acid diarrhoea, short-bowel effects, a mechanical stricture or coexisting functional symptoms. The two measure different things and both belong in the assessment.
Should the original or the modified Rutgeerts score be used?#
Record both. The original five-grade score is what the trial literature reports and what guidelines are written around, so it should always be documented. The i2a/i2b subdivision adds genuinely useful information about lesion location, but an analysis of the modification found it did not change determinations of recurrence or the need for intervention, so it informs a borderline decision rather than overriding the conventional threshold.
References
Original / primary reference
Validation and evidence
Clinical practice guidelines
- Nguyen GC, Loftus EV Jr, Hirano I, Falck-Ytter Y, Singh S, Sultan S; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. Gastroenterology. 2017;152(1):271-275.
- Gomollón F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3-25.